Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.
Collins
R
R
Clinical Trial Service Unit, Nuffield Department of Clinical Medicine, University of Oxford, United Kingdom.
Peto
R
R
Baigent
C
C
Sleight
P
P
D001241:Aspirin / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000139:chemically induced; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D001241:Aspirin